Elsevier

The Lancet

Volume 370, Issue 9583, 21–27 July 2007, Pages 204-206
The Lancet

Comment
Clinical update: new treatments for age-related macular degeneration

https://doi.org/10.1016/S0140-6736(07)61104-0Get rights and content

First page preview

First page preview
Click to open first page preview

References (18)

There are more references available in the full text version of this article.

Cited by (130)

  • Posterior cyclodialysis cleft following intravitreal injection

    2021, American Journal of Ophthalmology Case Reports
    Citation Excerpt :

    Intravitreal injections (IVIs) are among the most commonly performed ophthalmic procedures worldwide.1,2 Specifically, IVIs of anti-vascular endothelial growth factors are among mainstay treatments for complications of diabetic retinopathy, retinal vascular occlusions, and age-related macular degeneration.3–5 In general, IVIs are well-tolerated.

  • Trans-ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Gene Transduction after Intravitreal Vector Administration

    2019, Molecular Therapy Methods and Clinical Development
    Citation Excerpt :

    Intravitreal injection is favored over the subretinal vector administration because it is less invasive for vector delivery. Human clinical intravitreal injection of drugs is now quite common in using anti-VEGF compounds to treat neovascular complications of age-related macular degeneration43 and diabetic retinopathy.44 Currently, however, AAV delivery by intravitreal injection has limited capacity to transduce retinal cells, especially the RPE and photoreceptors.

View all citing articles on Scopus
View full text